Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and / or TSC2 Mutations

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
< Back to search results
This clinical trial matches:
Show Search Criteria
Status: Active

Description

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and / or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

Inclusion Criteria

  • Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Eligible patients should have a histologically confirmed locally advance or metastatic TCC who progressed after standard therapy
  • Patient must have TCCs tumors harboring a TSC1 or TSC2 mutation identified by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory
  • Patients must have TCC tumor tissue available for submission in a form of at least 10 unstained slides or formalin-fixed paraffin-embedded (FFPE) block (FFPE block highly recommended and preferred); if the tissue were previously sent to Yale Tumor Profiling Laboratory (TPL) for prescreening, additional tissue submission may not be required if sufficient remaining tissue is available; but, must first consult with the principle investigator
  • Patient must have developed disease progression during or following treatment with at least one platinum- containing regimen (e.g., gemcitabine/cisplatin [GC], methotrexate-vinblastine-doxorubicin-cisplatin [MVAC], carboplatin, gemcitabine [CarboGem]) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence, or must be unfit or ineligible for cisplatin-based chemotherapy; there is no restriction on the number of prior lines of chemotherapeutics agents received * Patients who progressed within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant regimen are considered second-line patients; therefore, these patients may be also eligible * Patients who are unfit or ineligible for cisplatin-based chemotherapy as defined by any one of the following criteria are eligible for this trial: ** Eastern Cooperative Oncology Group (ECOG) performance score of 2 ** Creatinine clearance < 60 mL/min ** A hearing loss (measured by audiometry) of 25 dB at two contiguous frequencies ** Grade >= 2 peripheral neuropathy
  • ECOG performance status =< 2 (Karnofsky >= 60 %)
  • Life expectancy of greater than 12 weeks
  • Hemoglobin >= 9 g/dL
  • Fasting serum glucose =< 130 mg/dL
  • Glycosylated hemoglobin measurement (HbA1c) < 7.0%
  • Fasting triglycerides =< 300 mg/dL
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin within normal institutional limits
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 × institutional upper limit of normal (ULN) and =< 5 ULN if liver metastases are present
  • Creatinine =< 1.5 x upper normal institutional limits (UNL) OR creatinine clearance >= 40 mL/min based either on Cockroft-Gault estimate or based on urine collection (12 or 24 hour)
  • Patients with controlled diabetes are allowed on study; controlled diabetes is defined as fasting blood sugar (FBS) < 130 mg/dL, and patients whose FBS can be brought in this range with medical therapy are eligible for trial inclusion
  • Women of childbearing age should avoid becoming pregnant while taking any mTOR inhibitor including MLN0128 (TAK-228) *Female patients must: ** Be postmenopausal for at least 1 year before the screening visit, OR ** Be surgically sterile, OR ** If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [e.g., USPI, SmPC, etc.;]) after the last dose of study drug, OR ** Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient; NOTE: periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception; female and male condoms should not be used together * Male patients, even if surgically sterilized (i.e., status postvasectomy), must: ** Agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR ** Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient (NOTE: periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception; female and male condoms should not be used together) ** AND agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug
  • Ability to swallow oral medications
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Patients who are receiving any other investigational agents
  • Patients with known untreated brain metastases should be excluded from this clinical trial
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
  • Subjects who are on systemic corticosteroids (intravenous (IV) or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis
  • Subjects taking strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4, CYP2C19 or CYP2C9 within 1 week preceding the first dose of MLN0128 (TAK-228); if a subject requires treatment with strong inhibitors and/or inducers of CYP3A4, CYP2C19 and/or CYP2C9, alternative treatment must be considered; if no alternative is available, one such medication may be allowed after discussing with the study principle investigator
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patient’s general health and cluster of differentiation (CD)4 counts are within acceptable levels
  • Patients with symptomatic/untreated central nervous system (CNS) metastases; patients with treated and stable brain metastasis are allowed
  • Patients with impaired cardiac function or clinically significant cardiac disease; patients with baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval > 480 milliseconds, or history of congenital long QT syndrome, or torsades de pointes) will not be allowed; no ischemic myocardial or cerebrovascular event, class III or IV heart failure, placement of pacemaker, or pulmonary embolism within six months of receiving first dose of MLN0128 (TAK-228)
  • Patients with untreated or active hepatitis B or C infection
  • Significant active cardiovascular or pulmonary disease at the time of study entry, including * Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg) * Pulmonary hypertension * Uncontrolled asthma or oxygen (O2) saturation < 90% by ABG (arterial blood gas) analysis or pulse oximetry on room air * Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement * Medically significant (symptomatic) bradycardia
  • Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228)
  • Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for 7 days before their first dose of study drugs
  • History of any of the following within the last 6 months prior to study entry: * Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures * Ischemic cerebrovascular event, including transient ischemic attack (TIA) and artery revascularization procedures * Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia) * Pulmonary embolism
  • Subjects who have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)
  • Patients who received prior PI3K, AKT or mTOR inhibitors are not allowed
  • Patients who received radiation therapy within the last 4 weeks; radiation exposure may not exceed 30% of marrow area

Locations & Contacts

California

Los Angeles
Los Angeles County-USC Medical Center
Status: Active
Contact: David Ian Quinn
Phone: 323-865-0451
USC / Norris Comprehensive Cancer Center
Status: Active
Contact: David Ian Quinn
Phone: 323-865-0451
Pasadena
Keck Medical Center of USC Pasadena
Status: Active
Contact: David Ian Quinn
Phone: 323-865-0451
Sacramento
University of California Davis Comprehensive Cancer Center
Status: Active
Contact: Primo Nery Lara
Phone: 916-734-3089

Connecticut

New Haven
Smilow Cancer Center / Yale-New Haven Hospital
Status: Active
Contact: Joseph Woong Kim
Phone: 855-476-4569
Yale University
Status: Active
Contact: Joseph Woong Kim
Phone: 203-494-3287 Email: joseph.w.kim@yale.edu

Illinois

Chicago
Northwestern University
Status: Active
Contact: Alicia Katherine Morgans
Phone: 312-695-1301 Email: cancer@northwestern.edu

Kansas

Fairway
University of Kansas Clinical Research Center
Status: Active
Contact: Rahul A. Parikh
Phone: 913-945-7552 Email: ctnursenav@kumc.edu

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: Active
Contact: Noah M. Hahn
Phone: 410-955-8804 Email: jhcccro@jhmi.edu

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: Active
Contact: David J. Kwiatkowski
Phone: 877-442-3324
Brigham and Women's Hospital
Status: Active
Contact: David J. Kwiatkowski
Phone: 877-442-3324
Dana-Farber Cancer Institute
Status: Active
Contact: David J. Kwiatkowski
Phone: 877-442-3324
Massachusetts General Hospital Cancer Center
Status: Active
Contact: David J. Kwiatkowski
Phone: 877-442-3324

Michigan

Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: Active
Contact: Ajjai Shivaram Alva
Phone: 800-865-1125

Nebraska

Bellevue
Nebraska Medicine-Bellevue
Status: Active
Contact: Benjamin Addison Teply
Phone: 402-559-6941 Email: unmcrsa@unmc.edu
Omaha
Nebraska Medicine-Village Pointe
Status: Active
Contact: Benjamin Addison Teply
Phone: 402-559-5600
University of Nebraska Medical Center
Status: Active
Contact: Benjamin Addison Teply
Phone: 402-559-6941 Email: unmcrsa@unmc.edu

North Carolina

Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: Active
Contact: Matthew Ivan Milowsky
Phone: 877-668-0683 Email: cancerclinicaltrials@med.unc.edu

Pennsylvania

Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: Active
Contact: Leonard Joseph Appleman
Phone: 412-647-8073

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: Active
Contact: David D. Chism
Phone: 800-811-8480

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To determine the overall response rate (ORR) defined as complete response (CR) and partial response (PR) in patients with locally advanced or metastatic transitional cell carcinoma (TCC) harboring a TSC1 mutation.

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of sapanisertib (MLN0128) (TAK-228) in patients with locally advanced or metastatic TCC harboring a TSC1 or TSC2 mutation.

II. To evaluate progression free survival (PFS) and overall survival (OS).

TERTIARY OBJECTIVES:

I. To determine the ORR in patients with locally advanced or metastatic TCC harboring a TSC2 mutation.

II. To evaluate toxicity, PFS, and OS in TSC2 mutation patients.

OUTLINE:

Patients receive sapanisertib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks and every 6 months thereafter.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Yale University Cancer Center LAO

Principal Investigator
Joseph Woong Kim

Trial IDs

Primary ID 9767
Secondary IDs NCI-2015-00121, 1505015958
Clinicaltrials.gov ID NCT03047213